Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer

NCT01388647 is registered in ClinicalTrials.gov with Vector Oncology as lead sponsor.

NCT NCT01388647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01388647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer
Lead sponsor
Vector Oncology
Phase
Phase 1/2
Overall status
Terminated
Start date
August 31, 2011
Completion date
September 30, 2014
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive breast cancer